The prostate cancer risk locus at 10q11 is associated with DNA repair capacity

DNA Repair

Volumn 11, Issue 8, 2012, Pages 693-701

  Rinckleb, Antje E ^a   Surowy, Harald M ^a,b   Luedeke, Manuel ^a   Varga, Dominic ^a   Schrader, Mark ^a   Hoegel, Josef ^a   Vogel, Walther ^a   Maier, Christiane ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Micronucleus assay; Mitotic delay; MSMB; PARG; Prostate cancer; Rs10993994

Indexed keywords

DOUBLE STRANDED DNA; NKX3 1 PROTEIN; PARG PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER RISK; CHROMOSOME 10Q; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; HOMOZYGOSITY; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MICRONUCLEUS TEST; MITOSIS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; CHROMOSOMES, HUMAN, PAIR 10; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; GAMMA RAYS; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LYMPHOCYTES; MALE; MICRONUCLEUS TESTS; MITOTIC INDEX; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; YOUNG ADULT;

EID: 84864294222     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2012.05.003     Document Type: Article

References (55)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 2000, 343:78-85.
3. Al Olama A.A., Kote-Jarai Z., Giles G.G., Guy M., Morrison J., Severi G., Leongamornlert D.A., Tymrakiewicz M., Jhavar S., Saunders E., Hopper J.L., Southey M.C., Muir K.R., English D.R., Dearnaley D.P., Ardern-Jones A.T., Hall A.L., O'Brien L.T., Wilkinson R.A., Sawyer E., Lophatananon A., Horwich A., Huddart R.A., Khoo V.S., Parker C.C., Woodhouse C.J., Thompson A., Christmas T., Ogden C., Cooper C., Donovan J.L., Hamdy F.C., Neal D.E., Eeles R.A., Easton D.F. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 2009, 41:1058-1060.
4. Thomas G., Jacobs K.B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., Chatterjee N., Welch R., Hutchinson A., Crenshaw A., Cancel-Tassin G., Staats B.J., Wang Z., Gonzalez-Bosquet J., Fang J., Deng X., Berndt S.I., Calle E.E., Feigelson H.S., Thun M.J., Rodriguez C., Albanes D., Virtamo J., Weinstein S., Schumacher F.R., Giovannucci E., Willett W.C., Cussenot O., Valeri A., Andriole G.L., Crawford E.D., Tucker M., Gerhard D.S., Fraumeni J.F., Hoover R., Hayes R.B., Hunter D.J., Chanock S.J. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 2008, 40:310-315.
5. Eeles R.A., Kote-Jarai Z., Al Olama A.A., Giles G.G., Guy M., Severi G., Muir K., Hopper J.L., Henderson B.E., Haiman C.A., Schleutker J., Hamdy F.C., Neal D.E., Donovan J.L., Stanford J.L., Ostrander E.A., Ingles S.A., John E.M., Thibodeau S.N., Schaid D., Park J.Y., Spurdle A., Clements J., Dickinson J.L., Maier C., Vogel W., Dork T., Rebbeck T.R., Cooney K.A., Cannon-Albright L., Chappuis P.O., Hutter P., Zeegers M., Kaneva R., Zhang H.W., Lu Y.J., Foulkes W.D., English D.R., Leongamornlert D.A., Tymrakiewicz M., Morrison J., Ardern-Jones A.T., Hall A.L., O'Brien L.T., Wilkinson R.A., Saunders E.J., Page E.C., Sawyer E.J., Edwards S.M., Dearnaley D.P., Horwich A., Huddart R.A., Khoo V.S., Parker C.C., Van As N., Woodhouse C.J., Thompson A., Christmas T., Ogden C., Cooper C.S., Southey M.C., Lophatananon A., Liu J.F., Kolonel L.N., Le Marchand L., Wahlfors T., Tammela T.L., Auvinen A., Lewis S.J., Cox A., FitzGerald L.M., Koopmeiners J.S., Karyadi D.M., Kwon E.M., Stern M.C., Corral R., Joshi A.D., Shahabi A., McDonnell S.K., Sellers T.A., Pow-Sang J., Chambers S., Aitken J., Gardiner R.A., Batra J., Kedda M.A., Lose F., Polanowski A., Patterson B., Serth J., Meyer A., Luedeke M., Stefflova K., Ray A.M., Lange E.M., Farnham J., Khan H., Slavov C., Mitkova A., Cao G., Easton D.F. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 2009, 41:1116-1121.
6. Eeles R.A., Kote-Jarai Z., Giles G.G., Olama A.A., Guy M., Jugurnauth S.K., Mulholland S., Leongamornlert D.A., Edwards S.M., Morrison J., Field H.I., Southey M.C., Severi G., Donovan J.L., Hamdy F.C., Dearnaley D.P., Muir K.R., Smith C., Bagnato M., Ardern-Jones A.T., Hall A.L., O'Brien L.T., Gehr-Swain B.N., Wilkinson R.A., Cox A., Lewis S., Brown P.M., Jhavar S.G., Tymrakiewicz M., Lophatananon A., Bryant S.L., Horwich A., Huddart R.A., Khoo V.S., Parker C.C., Woodhouse C.J., Thompson A., Christmas T., Ogden C., Fisher C., Jamieson C., Cooper C.S., English D.R., Hopper J.L., Neal D.E., Easton D.F. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 2008, 40:316-321.
7. Kote-Jarai Z., Olama A.A., Giles G.G., Severi G., Schleutker J., Weischer M., Campa D., Riboli E., Key T., Gronberg H., Hunter D.J., Kraft P., Thun M.J., Ingles S., Chanock S., Albanes D., Hayes R.B., Neal D.E., Hamdy F.C., Donovan J.L., Pharoah P., Schumacher F., Henderson B.E., Stanford J.L., Ostrander E.A., Sorensen K.D., Dork T., Andriole G., Dickinson J.L., Cybulski C., Lubinski J., Spurdle A., Clements J.A., Chambers S., Aitken J., Gardiner R.A., Thibodeau S.N., Schaid D., John E.M., Maier C., Vogel W., Cooney K.A., Park J.Y., Cannon-Albright L., Brenner H., Habuchi T., Zhang H.W., Lu Y.J., Kaneva R., Muir K., Benlloch S., Leongamornlert D.A., Saunders E.J., Tymrakiewicz M., Mahmud N., Guy M., O'Brien L.T., Wilkinson R.A., Hall A.L., Sawyer E.J., Dadaev T., Morrison J., Dearnaley D.P., Horwich A., Huddart R.A., Khoo V.S., Parker C.C., Van As N., Woodhouse C.J., Thompson A., Christmas T., Ogden C., Cooper C.S., Lophatonanon A., Southey M.C., Hopper J.L., English D.R., Wahlfors T., Tammela T.L., Klarskov P., Nordestgaard B.G., Roder M.A., Tybjaerg-Hansen A., Bojesen S.E., Travis R., Canzian F., Kaaks R., Wiklund F., Aly M., Lindstrom S., Diver W.R., Gapstur S., Stern M.C., Corral R., Virtamo J., Cox A., Haiman C.A., Le Marchand L., Fitzgerald L., Kolb S., Kwon E.M., Karyadi D.M., Orntoft T.F., Borre M., Meyer A., Serth J., Yeager M., Berndt S.I., Marthick J.R., Patterson B., Wokolorczyk D., Batra J., Lose F., McDonnell S.K., Joshi A.D., Shahabi A., Rinckleb A.E., Ray A., Sellers T.A., Lin H.Y., Stephenson R.A., Farnham J., Muller H., Rothenbacher D., Tsuchiya N., Narita S., Cao G.W., Slavov C., Mitev V., Easton D.F., Eeles R.A. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet. 2011, 43:785-791.
8. Schumacher F.R., Berndt S.I., Siddiq A., Jacobs K.B., Wang Z., Lindstrom S., Stevens V.L., Chen C., Mondul A.M., Travis R.C., Stram D.O., Eeles R.A., Easton D.F., Giles G., Hopper J.L., Neal D.E., Hamdy F.C., Donovan J.L., Muir K., Al Olama A.A., Kote-Jarai Z., Guy M., Severi G., Gronberg H., Isaacs W.B., Karlsson R., Wiklund F., Xu J., Allen N.E., Andriole G.L., Barricarte A., Boeing H., Bueno-de-Mesquita H.B., Crawford E.D., Diver W.R., Gonzalez C.A., Gaziano J.M., Giovannucci E.L., Johansson M., Le Marchand L., Ma J., Sieri S., Stattin P., Stampfer M.J., Tjonneland A., Vineis P., Virtamo J., Vogel U., Weinstein S.J., Yeager M., Thun M.J., Kolonel L.N., Henderson B.E., Albanes D., Hayes R.B., Feigelson H.S., Riboli E., Hunter D.J., Chanock S.J., Haiman C.A., Kraft P. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet. 2011, 20:3867-3875.
9. Tsurusaki T., Koji T., Sakai H., Kanetake H., Nakane P.K., Saito Y. Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998, 35:109-116.
10. Pomerantz M.M., Shrestha Y., Flavin R.J., Regan M.M., Penney K.L., Mucci L.A., Stampfer M.J., Hunter D.J., Chanock S.J., Schafer E.J., Chan J.A., Tabernero J., Baselga J., Richardson A.L., Loda M., Oh W.K., Kantoff P.W., Hahn W.C., Freedman M.L. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010, 6:e1001204.
11. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J. Natl. Cancer Inst. 1999, 91:1310-1316.
12. Erkko H., Xia B., Nikkila J., Schleutker J., Syrjakoski K., Mannermaa A., Kallioniemi A., Pylkas K., Karppinen S.M., Rapakko K., Miron A., Sheng Q., Li G., Mattila H., Bell D.W., Haber D.A., Grip M., Reiman M., Jukkola-Vuorinen A., Mustonen A., Kere J., Aaltonen L.A., Kosma V.M., Kataja V., Soini Y., Drapkin R.I., Livingston D.M., Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319.
13. Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K., Qian C., Marks A.F., Slager S.L., Peterson B.J., Smith D.I., Cheville J.C., Blute M.L., Jacobsen S.J., Schaid D.J., Tindall D.J., Thibodeau S.N., Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet. 2003, 72:270-280.
14. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat. Protoc. 2007, 2:1084-1104.
15. Surowy H., Rinckleb A., Luedeke M., Stuber M., Wecker A., Varga D., Maier C., Hoegel J., Vogel W. Heritability of baseline and induced micronucleus frequencies. Mutagenesis 2011, 26:111-117.
16. Varga D., Johannes T., Jainta S., Schuster S., Schwarz-Boeger U., Kiechle M., Patino G.B., Vogel W. An automated scoring procedure for the micronucleus test by image analysis. Mutagenesis 2004, 19:391-397.
17. Freedman M.L., Haiman C.A., Patterson N., McDonald G.J., Tandon A., Waliszewska A., Penney K., Steen R.G., Ardlie K., John E.M., Oakley-Girvan I., Whittemore A.S., Cooney K.A., Ingles S.A., Altshuler D., Henderson B.E., Reich D. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl. Acad. Sci. U.S.A 2006, 103:14068-14073.
18. Amundadottir L.T., Sulem P., Gudmundsson J., Helgason A., Baker A., Agnarsson B.A., Sigurdsson A., Benediktsdottir K.R., Cazier J.B., Sainz J., Jakobsdottir M., Kostic J., Magnusdottir D.N., Ghosh S., Agnarsson K., Birgisdottir B., Le Roux L., Olafsdottir A., Blondal T., Andresdottir M., Gretarsdottir O.S., Bergthorsson J.T., Gudbjartsson D., Gylfason A., Thorleifsson G., Manolescu A., Kristjansson K., Geirsson G., Isaksson H., Douglas J., Johansson J.E., Balter K., Wiklund F., Montie J.E., Yu X., Suarez B.K., Ober C., Cooney K.A., Gronberg H., Catalona W.J., Einarsson G.V., Barkardottir R.B., Gulcher J.R., Kong A., Thorsteinsdottir U., Stefansson K. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 2006, 38:652-658.
19. Zheng S.L., Sun J., Cheng Y., Li G., Hsu F.C., Zhu Y., Chang B.L., Liu W., Kim J.W., Turner A.R., Gielzak M., Yan G., Isaacs S.D., Wiley K.E., Sauvageot J., Chen H.S., Gurganus R., Mangold L.A., Trock B.J., Gronberg H., Duggan D., Carpten J.D., Partin A.W., Walsh P.C., Xu J., Isaacs W.B. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J. Natl. Cancer Inst. 2007, 99:1525-1533.
20. Haiman C.A., Patterson N., Freedman M.L., Myers S.R., Pike M.C., Waliszewska A., Neubauer J., Tandon A., Schirmer C., McDonald G.J., Greenway S.C., Stram D.O., Le Marchand L., Kolonel L.N., Frasco M., Wong D., Pooler L.C., Ardlie K., Oakley-Girvan I., Whittemore A.S., Cooney K.A., John E.M., Ingles S.A., Altshuler D., Henderson B.E., Reich D. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 2007, 39:638-644.
21. Sun J., Zheng S.L., Wiklund F., Isaacs S.D., Purcell L.D., Gao Z., Hsu F.C., Kim S.T., Liu W., Zhu Y., Stattin P., Adami H.O., Wiley K.E., Dimitrov L., Sun J., Li T., Turner A.R., Adams T.S., Adolfsson J., Johansson J.E., Lowey J., Trock B.J., Partin A.W., Walsh P.C., Trent J.M., Duggan D., Carpten J., Chang B.L., Gronberg H., Isaacs W.B., Xu J. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet. 2008, 40:1153-1155.
22. Gudmundsson J., Sulem P., Steinthorsdottir V., Bergthorsson J.T., Thorleifsson G., Manolescu A., Rafnar T., Gudbjartsson D., Agnarsson B.A., Baker A., Sigurdsson A., Benediktsdottir K.R., Jakobsdottir M., Blondal T., Stacey S.N., Helgason A., Gunnarsdottir S., Olafsdottir A., Kristinsson K.T., Birgisdottir B., Ghosh S., Thorlacius S., Magnusdottir D., Stefansdottir G., Kristjansson K., Bagger Y., Wilensky R.L., Reilly M.P., Morris A.D., Kimber C.H., Adeyemo A., Chen Y., Zhou J., So W.Y., Tong P.C., Ng M.C., Hansen T., Andersen G., Borch-Johnsen K., Jorgensen T., Tres A., Fuertes F., Ruiz-Echarri M., Asin L., Saez B., van Boven E., Klaver S., Swinkels D.W., Aben K.K., Graif T., Cashy J., Suarez B.K., van Vierssen T.O., Frigge M.L., Ober C., Hofker M.H., Wijmenga C., Christiansen C., Rader D.J., Palmer C.N., Rotimi C., Chan J.C., Pedersen O., Sigurdsson G., Benediktsson R., Jonsson E., Einarsson G.V., Mayordomo J.I., Catalona W.J., Kiemeney L.A., Barkardottir R.B., Gulcher J.R., Thorsteinsdottir U., Kong A., Stefansson K. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 2007, 39:977-983.
23. Kote-Jarai Z., Easton D.F., Stanford J.L., Ostrander E.A., Schleutker J., Ingles S.A., Schaid D., Thibodeau S., Dork T., Neal D., Donovan J., Hamdy F., Cox A., Maier C., Vogel W., Guy M., Muir K., Lophatananon A., Kedda M.A., Spurdle A., Steginga S., John E.M., Giles G., Hopper J., Chappuis P.O., Hutter P., Foulkes W.D., Hamel N., Salinas C.A., Koopmeiners J.S., Karyadi D.M., Johanneson B., Wahlfors T., Tammela T.L., Stern M.C., Corral R., McDonnell S.K., Schurmann P., Meyer A., Kuefer R., Leongamornlert D.A., Tymrakiewicz M., Liu J.F., O'Mara T., Gardiner R.A., Aitken J., Joshi A.D., Severi G., English D.R., Southey M., Edwards S.M., Al Olama A.A., Eeles R.A. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2052-2061.
24. Goh C.L., Schumacher F.R., Easton D., Muir K., Henderson B., Kote-Jarai Z., Eeles R.A. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J. Intern. Med. 2012, 271:353-365.
25. Freedman M.L., Monteiro A.N., Gayther S.A., Coetzee G.A., Risch A., Plass C., Casey G., De Biasi M., Carlson C., Duggan D., James M., Liu P., Tichelaar J.W., Vikis H.G., You M., Mills I.G. Principles for the post-GWAS functional characterization of cancer risk loci. Nat. Genet. 2011, 43:513-518.
26. Akamatsu S., Takata R., Ashikawa K., Hosono N., Kamatani N., Fujioka T., Ogawa O., Kubo M., Nakamura Y., Nakagawa H. A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum. Mol. Genet. 2010, 19:4265-4272.
27. Li P., Yu X., Ge K., Melamed J., Roeder R.G., Wang Z. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am. J. Pathol. 2002, 161:1467-1474.
28. Mestayer C., Blanchere M., Jaubert F., Dufour B., Mowszowicz I. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 2003, 56:192-200.
29. Bowen C., Stuart A., Ju J.H., Tuan J., Blonder J., Conrads T.P., Veenstra T.D., Gelmann E.P. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res. 2007, 67:455-464.
30. Bowen C., Gelmann E.P. NKX3.1 activates cellular response to DNA damage. Cancer Res. 2010, 70:3089-3097.
31. Erbaykent-Tepedelen B., Ozmen B., Varisli L., Gonen-Korkmaz C., Debelec-Butuner B., Muhammed S.H., Yilmazer-Cakmak O., Korkmaz K.S. NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines. Biochem. Biophys. Res. Commun. 2011, 414:123-128.
32. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R., Abate-Shen C., Shen M.M. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999, 13:966-977.
33. Ghoussaini M., Song H., Koessler T., Al Olama A.A., Kote-Jarai Z., Driver K.E., Pooley K.A., Ramus S.J., Kjaer S.K., Hogdall E., DiCioccio R.A., Whittemore A.S., Gayther S.A., Giles G.G., Guy M., Edwards S.M., Morrison J., Donovan J.L., Hamdy F.C., Dearnaley D.P., Ardern-Jones A.T., Hall A.L., O'Brien L.T., Gehr-Swain B.N., Wilkinson R.A., Brown P.M., Hopper J.L., Neal D.E., Pharoah P.D., Ponder B.A., Eeles R.A., Easton D.F., Dunning A.M. Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl. Cancer Inst. 2008, 100:962-966.
34. Pomerantz M.M., Beckwith C.A., Regan M.M., Wyman S.K., Petrovics G., Chen Y., Hawksworth D.J., Schumacher F.R., Mucci L., Penney K.L., Stampfer M.J., Chan J.A., Ardlie K.G., Fritz B.R., Parkin R.K., Lin D.W., Dyke M., Herman P., Lee S., Oh W.K., Kantoff P.W., Tewari M., McLeod D.G., Srivastava S., Freedman M.L. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009, 69:5568-5574.
35. Pomerantz M.M., Ahmadiyeh N., Jia L., Herman P., Verzi M.P., Doddapaneni H., Beckwith C.A., Chan J.A., Hills A., Davis M., Yao K., Kehoe S.M., Lenz H.J., Haiman C.A., Yan C., Henderson B.E., Frenkel B., Barretina J., Bass A., Tabernero J., Baselga J., Regan M.M., Manak J.R., Shivdasani R., Coetzee G.A., Freedman M.L. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 2009, 41:882-884.
36. Ahmadiyeh N., Pomerantz M.M., Grisanzio C., Herman P., Jia L., Almendro V., He H.H., Brown M., Liu X.S., Davis M., Caswell J.L., Beckwith C.A., Hills A., Macconaill L., Coetzee G.A., Regan M.M., Freedman M.L. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9742-9746.
37. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., Li F. The c-Myc target gene network. Semin. Cancer Biol. 2006, 16:253-264.
38. Karn J., Watson J.V., Lowe A.D., Green S.M., Vedeckis W. Regulation of cell cycle duration by c-myc levels. Oncogene 1989, 4:773-787.
39. Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3940-3944.
40. Menssen A., Epanchintsev A., Lodygin D., Rezaei N., Jung P., Verdoodt B., Diebold J., Hermeking H. c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 2007, 6:339-352.
41. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
42. Mao Z., Bozzella M., Seluanov A., Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) 2008, 7:1765-1771.
43. Chang B.L., Cramer S.D., Wiklund F., Isaacs S.D., Stevens V.L., Sun J., Smith S., Pruett K., Romero L.M., Wiley K.E., Kim S.T., Zhu Y., Zhang Z., Hsu F.C., Turner A.R., Adolfsson J., Liu W., Kim J.W., Duggan D., Carpten J., Zheng S.L., Rodriguez C., Isaacs W.B., Gronberg H., Xu J. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum. Mol. Genet. 2009, 18:1368-1375.
44. Lou H., Yeager M., Li H., Bosquet J.G., Hayes R.B., Orr N., Yu K., Hutchinson A., Jacobs K.B., Kraft P., Wacholder S., Chatterjee N., Feigelson H.S., Thun M.J., Diver W.R., Albanes D., Virtamo J., Weinstein S., Ma J., Gaziano J.M., Stampfer M., Schumacher F.R., Giovannucci E., Cancel-Tassin G., Cussenot O., Valeri A., Andriole G.L., Crawford E.D., Anderson S.K., Tucker M., Hoover R.N., Fraumeni J.F., Thomas G., Hunter D.J., Dean M., Chanock S.J. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7933-7938.
45. Lilja H., Abrahamsson P.A. Three predominant proteins secreted by the human prostate gland. Prostate 1988, 12:29-38.
46. Chan P.S., Chan L.W., Xuan J.W., Chin J.L., Choi H.L., Chan F.L. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 1999, 41:99-109.
47. Vanaja D.K., Cheville J.C., Iturria S.J., Young C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003, 63:3877-3882.
48. Garde S.V., Basrur V.S., Li L., Finkelman M.A., Krishan A., Wellham L., Ben Josef E., Haddad M., Taylor J.D., Porter A.T., Tang D.G. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999, 38:118-125.
49. Shukeir N., Arakelian A., Kadhim S., Garde S., Rabbani S.A. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res. 2003, 63:2072-2078.
50. Lamy S., Ruiz M.T., Wisniewski J., Garde S., Rabbani S.A., Panchal C., Wu J.J., Annabi B. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int. J. Cancer 2006, 118:2350-2358.
51. Whitaker H.C., Warren A.Y., Eeles R., Kote-Jarai Z., Neal D.E. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010, 70:333-340.
52. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
53. Ame J.C., Fouquerel E., Gauthier L.R., Biard D., Boussin F.D., Dantzer F., de Murcia G., Schreiber V. Radiation-induced mitotic catastrophe in PARG-deficient cells. J. Cell Sci. 2009, 122:1990-2002.
54. Baeyens A., Thierens H., Claes K., Poppe B., Messiaen L., De Ridder L., Vral A. Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br. J. Cancer 2002, 87:1379-1385.
55. Varga D., Hoegel J., Maier C., Jainta S., Hoehne M., Patino-Garcia B., Michel I., Schwarz-Boeger U., Kiechle M., Kreienberg R., Vogel W. On the difference of micronucleus frequencies in peripheral blood lymphocytes between breast cancer patients and controls. Mutagenesis 2006, 21:313-320.